OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SECL55

Suntar Eco-City Ltd

PharmaceuticalsVerified

Suntar Eco-City Ltd's capital structure and liquidity position cannot be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company's liquidity risk remains unknown, and there is no available data to evaluate its financial flexibility or short-term obligations. Profitability and return metrics for Suntar Eco-City Ltd are not available for comparison with industry benchmarks. The lack of financial data prevents an assessment of its operating margins, return on invested capital, or other key performance indicators that would be relevant for a pharmaceutical company. Segment and geographic exposure details are not disclosed in the available data. The company's revenue concentration by product line or geographic region is unknown, which limits the ability to assess diversification risks or growth opportunities. Growth trajectory and future performance expectations are not quantifiable due to the absence of historical revenue data and forward-looking guidance. The company's outlook for the current and next fiscal years remains undefined, and there are no numeric deltas to indicate expected changes in revenue or profitability. Risk factors for Suntar Eco-City Ltd include a low dilution potential, as the number of basic and diluted shares outstanding is identical, indicating no imminent share issuance. However, the lack of liquidity data and the absence of going-concern language in the source documents suggest potential financial instability or uncertainty. Recent events and filings for Suntar Eco-City Ltd are not disclosed in the available data. There are no transcripts or filings to indicate recent strategic moves, regulatory actions, or operational developments that could impact the company's performance.

30-day price · SECL(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanySuntar Eco-City Ltd
TickerSECL.SI
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Suntar Eco-City Ltd operates in the Pharmaceuticals & Medical Research industry, focusing on pharmaceuticals and medical research activities.

Classification. Suntar Eco-City Ltd is classified under the Pharmaceuticals & Medical Research industry within the Healthcare economic sector, with a confidence level of 0.92.

Suntar Eco-City Ltd's capital structure and liquidity position cannot be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company's liquidity risk remains unknown, and there is no available data to evaluate its financial flexibility or short-term obligations. Profitability and return metrics for Suntar Eco-City Ltd are not available for comparison with industry benchmarks. The lack of financial data prevents an assessment of its operating margins, return on invested capital, or other key performance indicators that would be relevant for a pharmaceutical company. Segment and geographic exposure details are not disclosed in the available data. The company's revenue concentration by product line or geographic region is unknown, which limits the ability to assess diversification risks or growth opportunities. Growth trajectory and future performance expectations are not quantifiable due to the absence of historical revenue data and forward-looking guidance. The company's outlook for the current and next fiscal years remains undefined, and there are no numeric deltas to indicate expected changes in revenue or profitability. Risk factors for Suntar Eco-City Ltd include a low dilution potential, as the number of basic and diluted shares outstanding is identical, indicating no imminent share issuance. However, the lack of liquidity data and the absence of going-concern language in the source documents suggest potential financial instability or uncertainty. Recent events and filings for Suntar Eco-City Ltd are not disclosed in the available data. There are no transcripts or filings to indicate recent strategic moves, regulatory actions, or operational developments that could impact the company's performance.
Key takeaways
  • Suntar Eco-City Ltd's liquidity and capital structure cannot be assessed due to missing balance-sheet data.
  • Profitability and return metrics are not available for comparison with industry benchmarks.
  • Revenue concentration and geographic exposure are not disclosed, limiting diversification analysis.
  • Growth trajectory and future performance expectations are undefined due to lack of historical and forward-looking data.
  • Dilution risk is low, but liquidity risk remains unassessed, suggesting potential financial uncertainty.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$10.8M$91.0k$84.0k$369.0k
FY-3$15.8M$409.0k$465.0k$827.0k
FY-2$35.4M$643.0k$643.0k$744.0k
FY-1$10.2M$8.4M$8.2M$8.4M
FY0$6.2M$913.0k$626.0k$835.0k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$114.4M$89.5M$9.0M
FY-3$116.1M$90.0M$10.3M
FY-2$118.8M$90.6M$38.7M
FY-1$135.6M$98.8M$57.8M
FY0$126.0M$99.4M$59.6M
PeriodOCFCapExFCFSBC
FY-4-$544.0k$0.00$369.0k
FY-3-$1.8M$827.0k
FY-2-$1.7M-$266.0k$744.0k
FY-1$5.1M-$133.0k$8.4M
FY0-$7.4M-$304.0k$835.0k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricSECLActivity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity9.3% medp25 0.1% · p75 43.8%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 00:58 UTC#4d4f1efc
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 09:04 UTCJob: b09c2c78